Virbac has introduced Marfloquin®, a marbofloxacin-based antibiotic indicated for the treatment of multiple infectious diseases in cats and dogs. It is presented as a palatable, divisible tablet for once daily administration and is available in three tablet strengths:
5 mg for cats and small dogs
20 mg for medium sized dogs
80 mg for large dogs
Virbac Companion Animal Marketing Manager Simon Boulton MRCVS comments: ” Marbofloxacin is valued by practices for its efficacy in treating a wide range of skin, soft tissue, urinary tract and respiratory tract infections. The launch of Marfloquin gives them a cost-effective alternative and strengthens our existing antibiotic range, which includes Rilexine (cefalexin) and Enrox (enrofloxacin).
For more information vets are advised to contact their territory manager or call Virbac on 01359 243243.
vetreport
Related Posts
Animal Health | Resources | Veterinary Business | Veterinary Education Call for veterinary case studies to expand evidence base for faecal calprotectin testing
Resources | Veterinary Business | Veterinary Education | Veterinary Events and Conferences 
No Comment